1. Home
  2. IOVA vs APPN Comparison

IOVA vs APPN Comparison

Compare IOVA & APPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • APPN
  • Stock Information
  • Founded
  • IOVA 2007
  • APPN 1999
  • Country
  • IOVA United States
  • APPN United States
  • Employees
  • IOVA N/A
  • APPN N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • APPN Computer Software: Prepackaged Software
  • Sector
  • IOVA Health Care
  • APPN Technology
  • Exchange
  • IOVA Nasdaq
  • APPN Nasdaq
  • Market Cap
  • IOVA 2.6B
  • APPN 2.6B
  • IPO Year
  • IOVA N/A
  • APPN 2017
  • Fundamental
  • Price
  • IOVA $5.82
  • APPN $33.90
  • Analyst Decision
  • IOVA Strong Buy
  • APPN Hold
  • Analyst Count
  • IOVA 9
  • APPN 7
  • Target Price
  • IOVA $23.06
  • APPN $40.00
  • AVG Volume (30 Days)
  • IOVA 7.2M
  • APPN 504.4K
  • Earning Date
  • IOVA 02-26-2025
  • APPN 02-19-2025
  • Dividend Yield
  • IOVA N/A
  • APPN N/A
  • EPS Growth
  • IOVA N/A
  • APPN N/A
  • EPS
  • IOVA N/A
  • APPN N/A
  • Revenue
  • IOVA $90,858,000.00
  • APPN $617,022,000.00
  • Revenue This Year
  • IOVA $13,803.28
  • APPN $14.93
  • Revenue Next Year
  • IOVA $167.55
  • APPN $11.07
  • P/E Ratio
  • IOVA N/A
  • APPN N/A
  • Revenue Growth
  • IOVA 12751.20
  • APPN 13.14
  • 52 Week Low
  • IOVA $5.05
  • APPN $26.28
  • 52 Week High
  • IOVA $18.33
  • APPN $43.33
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 49.38
  • APPN 51.21
  • Support Level
  • IOVA $5.44
  • APPN $30.79
  • Resistance Level
  • IOVA $5.80
  • APPN $41.05
  • Average True Range (ATR)
  • IOVA 0.31
  • APPN 1.89
  • MACD
  • IOVA 0.09
  • APPN 0.13
  • Stochastic Oscillator
  • IOVA 82.43
  • APPN 37.43

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About APPN Appian Corporation

Appian is a low-code enterprise platform-as-a-service company focusing on business process management. The Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. Most of Appian's revenue is subscription based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform, Appian Cloud.

Share on Social Networks: